Research ArticleArticle
Association of Anti-Modified Citrullinated Vimentin with Subclinical Atherosclerosis in Early Rheumatoid Arthritis Compared with Anti-Cyclic Citrullinated Peptide
Amal M. El-Barbary, Elham M. Kassem, Mervat A.S. El-Sergany, Salwa A-M. Essa and Mohamed A. Eltomey
The Journal of Rheumatology March 2011, jrheum.101143; DOI: https://doi.org/10.3899/jrheum.101143
Amal M. El-Barbary
Elham M. Kassem
Mervat A.S. El-Sergany
Salwa A-M. Essa
In this issue
The Journal of Rheumatology
Vol. 50, Issue 5
1 May 2023
Association of Anti-Modified Citrullinated Vimentin with Subclinical Atherosclerosis in Early Rheumatoid Arthritis Compared with Anti-Cyclic Citrullinated Peptide
Amal M. El-Barbary, Elham M. Kassem, Mervat A.S. El-Sergany, Salwa A-M. Essa, Mohamed A. Eltomey
The Journal of Rheumatology Mar 2011, jrheum.101143; DOI: 10.3899/jrheum.101143
Association of Anti-Modified Citrullinated Vimentin with Subclinical Atherosclerosis in Early Rheumatoid Arthritis Compared with Anti-Cyclic Citrullinated Peptide
Amal M. El-Barbary, Elham M. Kassem, Mervat A.S. El-Sergany, Salwa A-M. Essa, Mohamed A. Eltomey
The Journal of Rheumatology Mar 2011, jrheum.101143; DOI: 10.3899/jrheum.101143